Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD

Authors Daniel E Hilleman, Mark A Malesker, Lee E Morrow, Dan Schuller

Published 30 June 2009 Volume 2009:4 Pages 253—263

DOI https://dx.doi.org/10.2147/COPD.S4620

Review by Single-blind

Peer reviewer comments 5

Daniel E Hilleman,1 Mark A Malesker,1 Lee E Morrow,2 Dan Schuller2

1Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska, USA; 2Division of Pulmonary and Critical Care Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA

Abstract: The long-term use of inhaled anticholinergic agents has recently been suggested to be associated with an excess risk of adverse cardiovascular (CV) outcomes in patients with COPD. We identified 15 published studies that reported on the association between long-term inhaled anticholinergic use and adverse CV outcomes. Only 3 of the studies were adequately designed randomized controlled trials (RCTs). The first RCT that suggested that anticholinergic agents increased the risk of adverse CV outcomes was the Lung Health Study (LHS). Smokers randomized to inhaled ipratropium had a significantly increased risk of CV death than smokers receiving placebo. The LHS results have been questioned as the statistical tests used in the study were not adjusted for multiple tests and endpoints, a convincing dose-effect relationship between ipratropium use and the adverse CV outcomes was not established, and most of the CV deaths in the ipratropium group occurred in patients who were non-compliant to ipratropium. The Investigating New Standards for Prophylaxis in Reducing Exacerbations (INSPIRE) was a RCT that compared the combination of salmeterol plus fluticasone against tiotropium in patients with COPD. All-cause mortality was significantly lower in the salmeterol plus fluticasone group (3%) compared to the tiotropium group (6%). Fatal CV events occurred in 1% of the salmeterol plus fluticasone group compared to 3% in the tiotropium group. The INSPIRE trial was not designed to be a mortality trial, lacked adequate adjudication of fatal outcomes, and lacked a full intention-to-treat analysis of the data. The Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial was a RCT comparing tiotropium and placebo in patients with COPD. Follow-up in UPLIFT was planned for 1440 days (4 years) plus 30 days (1470 days) of post-treatment follow-up. At 1440 days with 95% of patient outcome accounted for, tiotropium was associated with a significant 13% reduction in all-cause mortality compared to placebo. However, at 1470 days with only 75% of patient outcome accounted for, tiotropium was associated with a non-significant 11% reduction in all-cause mortality compared to placebo. The relative risks for serious CV events, heart failure, and myocardial infarction were all significantly lower with tiotropium than placebo. It is not certain why such a wide disparity in findings exists among the published studies evaluating the CV risks of inhaled anticholinergic agents. Prospective, adequately powered RCTs are needed to provide more evidence for the CV safety of tiotropium.

Keywords: COPD, anticholinergics, cardiovascular risk, evidence-based guidelines

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone

Robyn Teply, Jennifer Campbell, Daniel Hilleman

Journal of Asthma and Allergy 2010, 3:1-8

Published Date: 11 March 2010

Readers of this article also read:

The analyses of risk factors for COPD in the Li ethnic group in Hainan, People’s Republic of China

Ding YP, Xu JX, Yao JJ, Chen Y, He P, Ouyang YH, Niu H, Tian ZJ, Sun P

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2593-2600

Published Date: 30 November 2015

Lung microbiology and exacerbations in COPD

Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:555-569

Published Date: 31 August 2012

Care of elderly people by the general practitioner and the geriatrician in Belgium: a qualitative study of their relationship

Dagneaux I, Gilard I, De Lepeleire J

Journal of Multidisciplinary Healthcare 2012, 5:17-25

Published Date: 25 January 2012

Can dead space fraction predict the length of mechanical ventilation in exacerbated COPD patients?

Raymond Farah, Nicola Makhoul

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:437-441

Published Date: 25 November 2009

Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study

Niels H Chavannes, Tjard RJ Schermer, Emiel FM Wouters, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:431-436

Published Date: 19 November 2009

Tiotropium HandiHaler® in the treatment of COPD: A safety review

Steven Kesten, Bart Celli, Marc Decramer, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:397-409

Published Date: 28 October 2009

Alveolar epithelial and endothelial cell apoptosis in emphysema: What we know and what we need to know

Mathieu C Morissette, Julie Parent, Julie Milot

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:19-31

Published Date: 2 December 2008

Focusing on outcomes: Making the most of COPD interventions

Noreen M Clark, Julia A Dodge, Martyn R Partridge, Fernando J Martinez

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:61-77

Published Date: 7 October 2008